NEW ORLEANS, April 4 (Reuters) - Gilead Sciences Inc’s (GILD.O) heart drug Ranexa, while found to be effective in reducing chest pain in refractory angina patients, failed to cut hospitalizations in a small 100-patient study.
NEW ORLEANS, April 4 (Reuters) - Gilead Sciences Inc’s (GILD.O) heart drug Ranexa, while found to be effective in reducing chest pain in refractory angina patients, failed to cut hospitalizations in a small 100-patient study.
